Healthcare >> CEO Interviews >> January 10, 2005
JACQUELINE SHAN is President, Chief Executive Officer, Chief Scientific
Officer and co-Founder of CV Technologies Inc. and the co-discoverer of
COLD-fX', an anti-cold, anti-flu product which clinical trials show
reduces the risk of getting colds and flu. She formally assumed the
position of CEO in 2003 and immediately began an aggressive
commercialization program which resulted in a remarkable growth in
sales, profitability and market cap. Today COLD-fX is found on pharmacy
shelves in more than 4,000 retail outlets in Canada, including Wal-Mart
and Costco. Dr. Shan is the architect of CVT's core strategy of using
clinical trials and science to differentiate itself from the
competition. At the age of 15, Dr. Shan entered university in China in
pursuit of the first of two doctorates she has received. She was awarded
a PhD with distinction in Physiology at the University of Alberta,
Canada, in 1992, and a Doctor of Science in Pharmacology from Peking
Union Medical College in 1993. She is recognized by universities in
three countries (Adjunct Professor, University of Alberta; Distinguished
Visiting Investigator, National Research Institute of Chinese Medicine
in Taiwan; Visiting Professor, Peking Union Medical College/Chinese
Academy of Medical Sciences; Visiting Associate Professor, University of
Hong Kong). She has authored/co-authored 50 peer-reviewed scientific
papers. Dr. Shan's doctoral training in pharmacology, physiology and in
traditional Chinese medicine enables her to use modern medical research
approaches to understanding traditional and natural medicine. Most of
her research projects are focused on basic and clinical research,
process and formulation development for nurtraceutical/natural health
products. Dr. Shan entered industry in 1992 by co-founding two biotech
companies ' CV Technologies Inc. (CVT) and Herb Tech Inc. both of
Edmonton, Alberta, Canada. She has discovered/co-discovered 10 US and
PCT patented products and led an in-house team of 25 scientists (13
PhDs, two MDs) with expertise in pharmacology, neurochemistry,
immunology, process engineering, phytochemistry, analytical chemistry,
western and traditional medicine. She has been instrumental in building
CVT's extensive research collaborative programs with national and
international academic and industrial research and development
organizations. Additionally, she organizes and oversees CVT's regulatory
and clinical activity in Canada, the US, China, Hong Kong and Taiwan and
manages all aspects of intellectual property. Profile
and a picture of the things you're doing at the present time.
Dr. Shan: CV Technologies was founded in 1992 as a spinoff
